ERBB2 and breast cancer: We also carried out an analysis using the ROC plotter tool32 to investigate whether CPT-1A was a biomarker of sensitivity or resistance to endocrine therapy, HER2-directed therapy or chemotherapy in breast cancers, both in terms of complete pathological response (CPR) and relapse-free survival (RFS).